The main adverse effect of primaquine, and the other 8-aminoquinoline antimalarials, is dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (Luzzatto et al., 2020; Recht et al., 2014). Here, G6PD is linked to G6PD deficiency.